How to use minoxidil: foam or liquid, oral or topical

Source · Sun Pharmaceutical Industries (distributed by Ohm Laboratories) · The US over-the-counter Drug Facts label of a generic 5% minoxidil foam for men, as published on DailyMed. A label states the approved directions and warnings; it is not a study and gives no trial numbers beyond the one-line note on who was tested. Archived as the DailyMed page text on 2026-10-16 (copied from the minoxidil-results archive).

• The men's foam is used as half a capful, twice a day, on the thinning area, massaged in, then hands washed. “apply half a capful 2 times a day to the scalp in the hair loss area massage into scalp with fingers, then wash hands well”
• Using more, or more often, does not give better results. “using more or more often will not improve results”
• You have to keep using it to keep the regrowth; if you stop, hair loss starts again. “continued use is necessary to increase and keep your hair regrowth or hair loss will begin again”
• The label says results may show at 2 months, but some men need at least 4 months. “Results may occur at 2 months with twice a day usage. For some men, you may need to use this product for at least 4 months before you see results.”
• Stop and see a doctor if you get chest pain, a racing heart, faintness or dizziness, sudden weight gain, or swollen hands or feet. “chest pain, rapid heartbeat, faintness, or dizziness occurs sudden, unexplained weight gain occurs your hands or feet swell”

Source · Kenvue Brands / Johnson & Johnson Consumer Inc. · The US over-the-counter Drug Facts label of the brand-name 5% minoxidil liquid (solution) for men. A label states the approved directions and warnings; it is not a study. Archived as the full label text from the DailyMed SPL XML.

• The men's liquid is 1 mL with the dropper, twice a day, put directly on the thinning area. “apply one mL with dropper 2 times a day directly onto the scalp in the hair loss area”
• The liquid contains propylene glycol (the foam labels do not list it). “alcohol, propylene glycol, purified water”
• The label says the 5% liquid is not meant for frontal baldness or a receding hairline. “5% minoxidil topical solution is not intended for frontal baldness or receding hairline.”
• Stopping means hair loss begins again. “continued use is necessary to increase and keep your hair regrowth, or hair loss will begin again”
• In men's trials, 5% gave more regrowth than 2%. “In clinical studies with mostly white men aged 18-49 years with moderate degrees of hair loss, 5% minoxidil topical solution for men provided more hair regrowth than 2% minoxidil topical solution”
• The liquid is labelled for use on the skin only. “For external use only.”
• If swallowed, get medical help straight away. “If swallowed, get medical help or contact a Poison Control Center right away.”

Source · Kenvue Brands / Johnson & Johnson Consumer Inc. · The US over-the-counter Drug Facts label of the brand-name 5% minoxidil foam for women. A label states the approved directions and warnings; it is not a study. Archived as the full label text from the DailyMed SPL XML.

• The same 5% foam is labelled once a day for women (half a capful), against twice a day on the men's label. “apply half a capful once daily directly to the scalp in the hair loss area”
• Women may see results at 3 months; some need at least 6 months of once-daily use. “Results may occur at 3 months with once daily use. For some women, you may need to use this product once a day for at least 6 months before you see results.”
• The label says to stop and ask a doctor if unwanted facial hair grows or there is no regrowth after 6 months. “unwanted facial hair growth occurs you do not see hair regrowth in 6 months”
• The foam's inactive ingredients do not include propylene glycol. “butane, butylated hydroxytoluene, cetyl alcohol, citric acid, glycerin, isobutane, lactic acid, polysorbate 60, propane, purified water, SD alcohol 40-B, stearyl alcohol”
• The women's label says not to use it if the hair loss came with childbirth. “your hair loss is associated with childbirth”

Source · Olsen EA, Whiting D, Bergfeld W, Miller J, Hordinsky M, Wanser R, Zhang P, Kohut B · The trial behind the 5% foam: 352 men aged 18 to 49, double-blind against a placebo foam for 16 weeks, then 143 continued open-label to 52 weeks for safety only. It tests foam against placebo, not foam against liquid. Abstract only; the PubMed record lists 'Research Support, Non-U.S. Gov't' but does not name the funder.

• The foam was developed as a version of 5% minoxidil without propylene glycol. “a new 5% minoxidil topical formulation in a propylene glycol-free foam vehicle”
• 352 men were tested for 16 weeks against a placebo foam. “This was a 16-week, double-blind, placebo-controlled trial of 5% minoxidil topical foam (MTF) in 352 men, 18 to 49 years old.”
• Hair counts rose significantly more on the foam than on placebo at 16 weeks. “there was a statistically significant increase in (1) hair counts in the 5% MTF group versus placebo (P < .0001)”
• The authors note they did not measure effect beyond 16 weeks. “There was no collection of efficacy data beyond 16 weeks.”

Source · Friedman ES, Friedman PM, Cohen DE, Washenik K · Case reports from a New York University dermatology department on patients with itching and scaling from minoxidil liquid who were patch-tested. The abstract does not give the number of patients. It shows what caused the reaction in the people they tested, not how common it is. Abstract only.

• Some users of the liquid get an itchy, scaly scalp; the usual causes are irritation, allergy, or flared seborrheic dermatitis. “The most common causes of these symptoms include irritant contact dermatitis, allergic contact dermatitis, or an exacerbation of seborrheic dermatitis.”
• In most of the patients they patch-tested, the allergy was to propylene glycol, not to minoxidil. “Among the patients we patch tested, propylene glycol was found to be the contactant in a majority of cases, not the minoxidil itself.”
• People allergic to minoxidil itself cannot use any topical minoxidil. “Unfortunately, patients found to be allergic to minoxidil are no longer candidates for topical treatment of their alopecia with any preparations of minoxidil.”

Source · Blume-Peytavi U, Hillmann K, Dietz E, Canfield D, Garcia Bartels N · A randomized trial at Charité Berlin: 113 women used either 5% foam once a day or 2% liquid twice a day for 24 weeks. The women knew which product they had (the authors' stated limitation), and it compares different strengths as well as forms. The closest head-to-head foam vs liquid trial found. Abstract only; PubMed lists 'Research Support, Non-U.S. Gov't' without naming the funder.

• 113 women were randomized to once-daily 5% foam or twice-daily 2% liquid for 24 weeks. “A total of 113 women with androgenetic alopecia were randomized to 24 weeks of treatment with 5% MTF or 2% MTS.”
• Once-daily foam did at least as well as twice-daily liquid (slightly better, not significantly). “Once-daily 5% MTF is noninferior and as effective for stimulating hair growth as twice-daily 2% MTS in women with androgenetic alopecia”
• The foam caused less scalp intolerance, especially itching and dandruff. “Women randomized to 5% MTF experienced significantly lower rates of local intolerance (P = .046) especially in pruritus and dandruff compared with 2% MTS.”
• More women on foam agreed it did not interfere with styling their hair. “5% MTF was significantly superior to 2% MTS in participants' agreement with "the treatment does not interfere with styling my hair" (P = .002).”
• Participants were not blinded because the two products look different. “Because of differences in the formulations tested, study participants were not blinded to treatment.”

Source · American Health Packaging (repackaged label) · The US prescription label for minoxidil tablets, which are approved only for severe high blood pressure, at doses of 10 to 40 mg a day; hair-loss doses are far lower and off-label. Its warnings describe blood-pressure patients on full doses, not people taking low doses for hair. Archived as the DailyMed page text on 2026-10-16 (copied from the minox-vs-fin archive).

• The tablets carry a boxed warning: minoxidil can cause fluid around the heart and can worsen angina. “It can cause pericardial effusion, occasionally progressing to tamponade, and angina pectoris may be exacerbated.”
• The label says using minoxidil tablets to grow hair is not an approved use. “Use of minoxidil tablets, in any formulation, to promote hair growth is not an approved indication.”
• Tablets for blood pressure start at 5 mg once a day. “The recommended initial dosage of minoxidil tablets is 5 mg given as a single daily dose.”
• At blood-pressure doses, about 80% of patients grow longer, thicker, darker body hair, starting within 3 to 6 weeks. “Elongation, thickening, and enhanced pigmentation of fine body hair are seen in about 80% of patients taking minoxidil tablets. This develops within 3 to 6 weeks after starting therapy.”
• After stopping, new body hair growth stops, but it can take up to 6 months to look as before. “Upon discontinuation of minoxidil, new hair growth stops, but 1 to 6 months may be required for restoration to pretreatment appearance.”

Source · Penha MA, Miot HA, Kasprzak M, Müller Ramos P · A double-blind, placebo-controlled randomized trial at one clinic in Brazil: 90 men (Norwood 3V to 5V) took 5 mg oral minoxidil plus a placebo liquid, or 1 mL 5% liquid twice daily plus a placebo pill, for 24 weeks; 68 finished. Small and short. Funded by the Brazilian Dermatology Society fund (FUNADERM), no other disclosures. The publisher does not allow full-text XML; the archive is the PMC record's front matter (key points, abstract, disclosures).

• Over 24 weeks, 5 mg oral was not shown to be better than 5% topical in men. “In this study, oral minoxidil, 5 mg, once per day for 24 weeks did not demonstrate superiority over topical minoxidil, 5%, twice per day in men with AGA.”
• Photo ratings favoured oral at the crown, but not at the front. “According to the photographic analysis, oral minoxidil was superior to topical minoxidil on the vertex (24%; 95% CI, 0 to 48; P = .04) but not on the frontal scalp (12%; 95% CI, −12 to 36; P = .24).”
• About half the men on oral minoxidil got extra body hair; 14% got headaches. “The most common adverse effects in the oral minoxidil group were hypertrichosis (22 of 45 [49%]) and headache (6 of 45 [14%]).”
• The authors see oral as an option for men who prefer a pill or cannot tolerate topical. “can be an option for patients who prefer oral therapy or are intolerant to topical treatment”

Source · Dias FR, Yong SS, FitzGerald H, Sinclair RD, Bhoyrul B · A narrative review (PubMed search to November 2025) of topical, oral and sublingual minoxidil by authors at Sinclair Dermatology, Melbourne. It summarises other studies rather than adding data; we use it for its summaries of trials we could not read in full (Ramos 2020). Conflict of interest: the review states that Bhoyrul holds shares in Samson Clinical and Sinclair is its founder and director; no funding. Full text read.

• The liquid uses ethanol and propylene glycol to dissolve minoxidil; the foam uses other ingredients. “The solution formulation contains ethanol and propylene glycol, which are used as vehicles to enhance the solubility of minoxidil (Tata et al., 1994).”
• The review says scalp irritation is more common with the liquid because of its propylene glycol. “Scalp irritation is more frequent with the alcohol-based solution due to its propylene glycol content.”
• Itching and extra shedding early on are the most common side effects of topical minoxidil. “The most common side effects include pruritus and increased hair shedding during the initial phase of treatment (Hussein et al., 2024).”
• In Ramos 2020 (women), 1 mg oral and 5% topical grew density by 12% and 7.2%, a difference that was not significant. “After 24 weeks of treatment, the total hair density increased by 12% in women taking oral minoxidil and 7.2% in women applying topical minoxidil, but the difference between the two groups was not statistically significant.”
• Oral and sublingual minoxidil are not FDA-approved for hair loss; they are prescribed off-label. “It is worth reiterating that, unlike topical minoxidil, the oral and sublingual formulations are not FDA-approved and only prescribed off-label.”

Source · Randolph M, Tosti A · A review of 17 studies (634 patients) on oral minoxidil for hair loss, from PubMed searches to April 2020, by University of Miami dermatologists. Most included studies were small and uncontrolled. Abstract only; no conflict-of-interest statement in the PubMed record.

• Many people struggle with topical minoxidil because of twice-daily use, hair texture and scalp irritation. “many patients are poorly compliant because of the necessity to apply the medication twice a day, undesirable hair texture, and scalp irritation”
• The review found 17 studies with 634 patients. “A total of 17 studies with 634 patients were found discussing the use of oral minoxidil as the primary treatment modality for hair loss.”
• The authors conclude oral minoxidil is an option for healthy people who have trouble with topical forms. “Oral minoxidil was found to be an effective and well-tolerated treatment alternative for healthy patients having difficulty with topical formulations.”
• They say bigger randomized trials are needed to settle the best dose. “Larger randomized studies comparing the efficacy/safety of different doses with standardized objective measurements will be needed to clarify the best treatment protocol.”

Source · Gupta AK, Hall DC, Talukder M, Bamimore MA · A systematic review with meta-regression of 6 small studies (doses 0.25 to 5 mg a day) to see whether a higher oral dose means more hair and more side effects. Comparing averages across studies (an ecological regression) shows an association, not cause; the authors say randomized trials are needed. Authors are at Mediprobe Research Inc. (a research company) and the University of Toronto; no conflicts declared, no funding. Full text read.

• The six studies used doses from 0.25 to 5 mg a day. “across the eligible studies, the dosages ranged from 0.25 to 5 mg daily”
• Each extra 1 mg a day was linked with more hair density after 6 months. “increasing the dosage of oral minoxidil by 1 mg daily is significantly associated with an expected increase of 47.1 and 9.1 hairs/cm2 in total (p = 0.0071) and terminal (p = 0.0014) hair density, respectively, after 6 months”
• Each extra 1 mg a day was also linked with more risk of extra body hair and of heart-and-circulation side effects. “increasing the dosage of oral minoxidil by 1 mg daily is, on average, significantly associated with an increased risk of having hypertrichosis and cardiovascular adverse events by 17.6% (p = 0.0057) and 4.8% (p = 0.00382), respectively”
• In another analysis they cite, extra body hair affected 6.7% at 0.25 mg and 56.1% at 5 mg. “0.25 mg daily was associated with 6.7% of patients receiving hypertrichosis, while 5 mg daily was associated with a 56.1% risk (p < 0.001) [29]”
• Itching and scaling have also been reported with the foam, not only the liquid. “However, itching and scaling have also been reported with use of topical minoxidil foam [19, 23].”

Source · Panchaprateep R, Lueangarun S · An open-label, single-arm study in Bangkok: 30 men (Norwood 3 vertex to 5) took 5 mg oral minoxidil every morning for 24 weeks. No control group, so it cannot show how much is due to the drug. Funded by Chulalongkorn University and the Royal College of Physicians of Thailand; authors have nothing to disclose. Full text read.

• 30 men took 5 mg once a day for 24 weeks. “Thirty men aged 24–59 years with AGA types III vertex to V were treated with oral minoxidil 5 mg once daily for 24 weeks.”
• Nearly all (93%) grew extra body hair and 10% had swollen feet; no serious heart problems were seen. “Common side effects were hypertrichosis (93% of patients) and pedal edema (10%). No serious cardiovascular adverse events and abnormal laboratory findings were observed.”
• The foot swelling appeared after 1 to 2 months and went away on its own. “Pedal edema was present in three patients (10%) at 1–2 months into treatment, which spontaneously resolved after 2–3 months.”
• The authors explain early shedding: minoxidil pushes resting hairs into a new cycle, so more fall at the start. “Thus, shortening of the telogen phase and acceleration of the telogen–exogen phase lead to synchronization of the hair cycle and increased hair shedding after the initiation of minoxidil therapy [10].”
• They advise care in men with severe high blood pressure or heart risk. “However, oral minoxidil should be used carefully with men who have severe hypertension and increased risk for cardiovascular events.”

Source · Sinclair RD · An open-label case series of 100 women with pattern hair loss given one capsule a day of 0.25 mg minoxidil plus 25 mg spironolactone for 12 months, by a single author in Melbourne. No control group, and two drugs at once, so the effect of minoxidil alone cannot be separated. Abstract only; no conflict-of-interest statement in the PubMed record.

• 100 women took 0.25 mg minoxidil with 25 mg spironolactone once a day for a year. “Women newly diagnosed with a Sinclair stage 2-5 PHL were scored for hair shedding and hair density before and after 12 months of treatment with oral minoxidil 0.25 mg and spironolactone 25 mg.”
• Side effects were seen in 8 of the 100 women and were mostly mild. “Side effects were seen in eight women but were generally mild.”
• Blood pressure dropped only a little on average. “Mean change in blood pressure was -4.52 mmHg systolic and -6.48 mmHg diastolic.”
• The author calls for placebo-controlled studies. “Placebo-controlled studies to investigate this further are warranted.”

Source · Chen M, Weichert M, Guo W, Ruzic R, Briley J · A systematic review and meta-analysis (a short research letter, Stony Brook Dermatology) pooling studies of oral minoxidil at 5 mg a day or less that reported blood pressure. The abstract does not say how many studies; the included studies mostly lacked control groups. Abstract only; conflicts of interest: none disclosed.

• Low-dose oral minoxidil did not significantly change systolic or diastolic blood pressure. “LDOM did not significantly alter systolic blood pressure (MD: -0.13, 95% CI: -2.67-2.41) or diastolic blood pressure (MD: -1.25, 95% CI: -3.21-0.71).”
• Heart rate went up slightly, by under 3 beats a minute on average. “There was a significant increase in heart rate (MD: 2.67, 95% CI: 0.34-5.01).”
• 5% reported symptoms like low blood pressure, but no actual low-blood-pressure episodes were observed. “Hypotensive symptoms were reported in 119 patients (5.0%), but no hypotensive episodes were observed.”
• Extra body hair was the most common side effect and the top reason people stopped. “Hypertrichosis was the most frequent side effect, leading to 34.6% of discontinuations.”

Source · Vañó-Galván S, Pirmez R, Hermosa-Gelbard A, et al. (26 authors incl. Shapiro J, Tosti A, Sinclair R, Bhoyrul B) · A retrospective look back at the records of 1,404 patients (two-thirds women) at hair clinics in several countries who took low-dose oral minoxidil for at least 3 months. No control group, and side effects were taken from notes rather than measured prospectively. Abstract only; conflicts of interest: none disclosed.

• 1,404 patients were included, 943 women and 461 men. “A total of 1404 patients (943 women [67.2%] and 461 men [32.8%]) with a mean age of 43 years (range 8-86) were included.”
• The most common side effect was extra body or facial hair (15%); few stopped because of it. “The most frequent adverse effect was hypertrichosis (15.1%), which led to treatment withdrawal in 14 patients (0.5%).”
• Body-wide side effects were lightheadedness, fluid retention and a fast heartbeat, each under 2%. “Systemic adverse effects included lightheadedness (1.7%), fluid retention (1.3%), tachycardia (0.9%), headache (0.4%), periorbital edema (0.3%), and insomnia (0.2%)”
• No life-threatening side effects were seen. “No life-threatening adverse effects were observed.”
• The authors name the study's limits: looked back at records, no control group. “Retrospective design and lack of a control group.”

Source · Olsen EA, Dunlap FE, Funicella T, Koperski JA, Swinehart JM, Tschen EH, Trancik RJ · A 48-week, double-blind, placebo-controlled randomized trial at several centres: 393 men aged 18 to 49 applied 5% solution, 2% solution or placebo twice daily. It is the main evidence that 5% beats 2% in men. Abstract only; the PubMed record lists 'Research Support, Non-U.S. Gov't' but not the funder.

• 393 men used 5%, 2% or placebo liquid twice a day for 48 weeks. “A total of 393 men (18-49 years old) with AGA applied 5% topical minoxidil solution (n = 157), 2% topical minoxidil solution (n = 158), or placebo (vehicle for 5% solution; n = 78) twice daily.”
• At 48 weeks, 5% gave 45% more regrowth than 2%. “the magnitude of its effect was marked (45% more hair regrowth than 2% topical minoxidil at week 48)”
• The 5% worked sooner than the 2%. “Hair count data indicate that response to treatment occurred earlier with 5% compared with 2% topical minoxidil.”
• Itching and irritation were more common with 5% than with 2%. “An increased occurrence of pruritus and local irritation was observed with 5% topical minoxidil compared with 2% topical minoxidil.”